Particle

Welcome to Abcentra

We are a clinical-stage biopharma company developing new drugs for cardiovascular diseases.  Our pipeline focuses on patient populations at high-risk of cardiometabolic complications from underlying chronic inflammation.

Bullseye Icon

Target Oxidized Lipoproteins

Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.

How It Works

Antibody icon

Treat Inflammatory Disease

Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.

Learn More

Recent News

Shot of businesspeople having a meeting in an office

Abcentra Names Kevin B. Bacon, Ph.D. Chief Executive Officer

Experienced Industry Leader Elevates Research and Development Capabilities, Joins Company At An Important Development Juncture

Advancing the Treatment of Coronary Heart Disease by Targeting Arterial Inflammation

Responsible for over 840,400 deaths and nearly 1.8 million cases of heart attack and stroke each year, CVD is the leading cause of death in the U.S.

Abcentra Reducing Need for Surgery in Aortic Valve Disease

By targeting specific mechanisms, Abcentra aims to make a surgical disease into a medically treatable disease for patients at risk.